LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

Shares of PureTech Health plc (NASDAQ:PRTC – Get Free Report) were down 6.3% on Thursday . The stock traded as low as $17.04 and last traded at $17.55. Approximately 6,778 shares traded hands during ...

Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatment LYT-200 is currently ...

The FDA has also granted orphan drug designation to LYT-200 for the treatment of AML as well as a separate Fast Track designation for the treatment of recurrent/metastatic head and neck squamous ...

BOSTON - PureTech Health plc (NASDAQ:PRTC, LSE:PRTC) has announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to its investigational drug LYT-200 for the treatment ...